Log in | Create new account Free!
Nonalcoholic Steatohepatitis (NASH) is a growing concern globally, with its prevalence on the rise due to sedentary lifestyles and poor dietary habits. Understanding the intricacies of NASH is crucial for developing effective treatments, and researchers are increasingly turning to in vitro models to unravel the mysteries of this complex liver disease.
The advent of AI technology has revolutionized several sectors, one of which is drug development and validation. The potential of AI technology in informing the processes such as the development of antibodies and optimizing molecules is progressively substantial. AI technology has made it easier, faster, and more accurate to train models, validate antibodies, and optimize molecules for drug development.
The battle against emerging infectious diseases remains a critical frontier in the pursuit of global health security. Monkeypox, a rare but potentially severe viral infection, has recently come under the spotlight due to a surge in reported cases. Breakthroughs in monkeypox vaccine discovery, the development of mRNA vaccines, and innovative testing kits mark significant strides toward effective control and prevention.
Nonalcoholic steatohepatitis (NASH) is a growing global health concern characterized by liver inflammation and damage caused by the accumulation of fat. The development of effective drugs depends heavily on robust experimental models. This article explores the pivotal role of NASH in vitro models and NASH mouse models in advancing drug development strategies.
Glycans, also known as carbohydrates or polysaccharides, are fundamental constituents of all cellular life. They play essential roles in various biological processes, including cell-to-cell communication, immune response, and disease progression, among others. Accurate glycan purification, glycan identification, and anti-glycan antibody assays are crucial in advancing our understanding of glycans and their roles in biology and medicine.
Parasites are notorious for inflicting a broad spectrum of illnesses, often leaving catastrophic health impacts on their hosts. These microorganisms pose a major threat to global health, contributing significantly to the burden of diseases around the world. The discovery of parasite antibodies, therefore, is a pivotal breakthrough.
The intricacies of the human immune system have been profoundly explored in recent years, revealing a wealth of knowledge that has unlocked new opportunities and methodologies for fighting diseases. One promising discovery is the concept of immune checkpoint therapy. The technology and mechanisms necessary for immune checkpoint antibody development have been under intense focus, which offers hope for groundbreaking therapies and disease management.
As the biopharmaceutical industry explores innovative and novel ways to handle the complexities of drug formulation, artificial intelligence (AI) technology is experiencing a marked rise in incorporation. Processor-intensive tasks such as antibody engineering, which were once hindered by time and resource constraints, are now becoming quicker and more efficient thanks to AI.
Typically, during human disease modeling and cell-based therapies, the capacity to reprogram somatic cells to induce iPSCs has provided great value. Nowadays, iPSC derivatives have already reached the stage of clinical testing in human patients. Using different techniques to produce induced iPSCs requires that scientists choose the suitable reprogramming method for generating iPSCs, thus the resulting iPSCs enable them to be transitioned towards clinical applications effectively.
Recent reports have shown that the gut microbiome can affect systemic immunity and promote autoimmune diseases. This provides new ideas for the treatment of rheumatoid arthritis (RA) that next-generation probiotics (NGPs) may be useful. Creative Biolabs has been devoted to the development of NGPs for years. With the comprehensive technology platform and Ph.D. level scientists, we are capable of providing global researchers with high-quality NGPs development services.
